Dapagliflozin/metformin

Drug Profile

Dapagliflozin/metformin

Alternative Names: Dapagliflozin/metformin FDC; Metformin/dapagliflozin; Oxramet; Xigduo FDC; Xigduo XR; Xigduo XR FDC

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2016 Launched for Type-2 diabetes mellitus in South Korea (PO) before December 2016
  • 31 May 2016 AstraZeneca completes a phase I bioequivalence trial in Healthy volunteers in Russia prior to May 2016 (PO) (NCT02722239)
  • 01 Apr 2016 AstraZeneca completes a phase I trial in Healthy volunteers in USA (NCT02637037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top